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Abstract: This study was motivated by the need to provide more insight 
into the possible mechanism of the intermolecular interactions between 
antispasmodic drug drotaverine and one of the serum albumins (BSA), 
with the aim to indicate the most probable sites of these interactions. For 
this purpose both experimental (spectrofluorometric titration at various 
temperatures) and theoretical (molecular mechanics) methods have been 
applied. The obtained results clearly showed that drotaverine quenched 
BSA fluorescence, and the most probable mechanism is static quenching. 
The negative value of the theoretically predicted binding free Gibbs energy 
(-23.8 kJ/mol) confirmed the existence of the intermolecular interactions 
involving drotaverine and one tryptophan within BSA protein and was well 
agreed with the experimentally determined value of -25.2 kJ/mol. 
Keywords: bovine serum albumin, drotaverine, fluorescence quenching, 
phosphorescence, molecular docking. 
Introduction 
Due to their extraordinary binding properties, serum albumins are the main 
transporters of various small molecules including metabolites, waste products, 
toxins and many drugs. The binding affinity for serum albumins is one of the 
most important factors affecting the distribution and the active concentration of 
many administered drugs. Ligands bound to these transporters are distributed 
through the circulatory system to their place of function or disposal with no 
threat of precipitation or undesirable effects [1]. 
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Serum albumins are highly abundant transport proteins present in the blood 
plasma of mammals [2]. Their structure is composed of α-helices organized in 
three similar domains (I-III) each of which is further grouped into two 
subdomains (A and B), with six and four helices, respectively [3]. The evolution 
of serum albumins led them to contain several binding sites, allowing them to 
bind a variety of compounds [4] including two drug sites (Drug Site I and II) [1] 
which are responsible for interactions with the ligands of a dual 
lipophilic/anionic character. Drug site 1 is a pre-formed binding pocket within 
the core of subdomain IIA that comprises all six helices of the subdomain and a 
loop-helix feature contributed by subdomain IB. The interior of the pocket is 
predominantly apolar with two clusters of polar residues, the inner cluster 
towards the bottom of the pocket and the outer one at the pocket entrance. Drug 
site 2, 1 is topologically similar to site 1 since it is composed of all six helices of 
subdomain IIIA and comprises a pre-formed hydrophobic cavity with distinct 
polar features. In terms of shape, size and polarity, the two drug sites in Human 
Serum Albumin (HSA) are clearly distinguishable, which helps to account for the 
different binding specificities of the two pockets [1]. Previously reported 
structural data [1] showed that the two primary drug sites on HSA are highly 
adaptable binding cavities containing distinct sub-compartments, and reveal a 
range of secondary binding sites located widely across the protein. The shape and 
the particular distribution of basic and polar residues on the mainly hydrophobic 
interior walls that are involved in specific interactions with small ligands 
determine the binding specificities of the pockets.  
Although serum albumins domains exhibit extensive structural homology 
(Bovine Serum Albumin (BSA) and HSA have over 70% sequence identity and 
almost 90% sequence similarity [3]), they differ in the distribution of their 
binding sites. The principal regions of ligand binding to HSA and BSA are 
located in hydrophobic cavities in subdomains IIA and IIIA.  
HSA has one tryptophan (Trp214) located in the subdomain IIA (inside the 
DS1 cavity), while BSA has two tryptophanyl residues (Trp213 and Trp134). 
The location of Trp213 is the same as Trp214 (in HSA), while Trp134 is inside 
the cavity of subdomain IB [5,6]. Due to the presence of tryptophanyl residue(s) 
in serum albumins, it is possible to apply spectroscopic methods  to study ligand 
binding to these proteins. 
Drotaverine 1-(3,4-diethoxybenzilidene)-6,7-diethoxy-1,2,3,4-tetrahydroiso-
quinoline) is an antispasmodic drug used in the treatment of smooth muscle 
spasm. It is a selective phosphodiesterase IV inhibitor preventing the hydrolysis 
of cyclic AMP leading to smooth muscle relaxation. It acts directly on smooth 
muscle and therefore has no anticholinergic effects reducing the number of side 
effects. It is used in treating renal colic and has also been used to accelerate labor, 
but not reduce pain [7,8]. In the structure of drotaverine, shown in Figure 1, the 
presence of a tetrahydroisoquinoline ring and phenyl group may be noticed 
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which provide a high level of conjugation and π electrons, thus enabling its 
detection by UV-Vis and fluorescence spectroscopy. 
 
 
Figure 1. The structure of drotaverine 
In this study the intermolecular interactions between drotaverine and BSA 
were investigated with the aim to provide more insight into the possible 
mechanism of binding of this drug to serum albumins and to its 
pharmacokinetics. For this purpose both spectroscopic (steady state and time 
resolved fluorescence) and molecular modeling tools (AutoDock 4.2) were used 
which allowed to estimate the thermodynamic parameters characterizing binding 
of this drug to serum albumin and also to indicate the possible location of the 
binding sites. 
Experimental 
Materials 
BSA, drotaverine, potassium iodide (KI), sodium sulfite (Na2SO3) purchased 
from Sigma-Aldrich were of the highest purity grade and were used without 
further purification. Stock solutions of phosphate buffer (1 M), Na2SO3 (0.1 M) 
and KI (1 M) were freshly prepared using high-purity water (18.2 MΩ) from 
Milli-Q system. Stock solution of BSA (10 µM) was prepared using 0.05 M 
phosphate buffer (pH 7). Since the solubility of drotaverine in water is very low, 
the stock solution of this drug (1 mM) was prepared using 2-propanol. 
Methods 
Absorption measurements were made using a Nicolet Evolution 300 UV-Vis 
spectrophotometer from Thermo Electron Corporation using Vision Pro program. 
Measurements were carried out within the range of 200-400 nm, with scan speed 
120 nm/min and bandwidth 1.5 nm. 
Steady-state fluorescence measurements were performed with a FluoroMax4 
(JobinYvonSpex) spectrofluorometer, using excitation wavelengths of 295 nm 
and 370 nm for BSA and drotaverine, respectively. All measurements were 
performed in a standard quartz cuvette at 20°C. 
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Fluorescence lifetime measurements were carried out at 20°C with a 
FL900CDT time-correlated single photon counting fluorometer from Edinburgh 
Analytical Instruments. The excitation and emission wavelengths were set to 295 
nm and 350 nm, respectively. Data acquisition and analysis were performed 
using the software provided by Edinburgh Analytical Instrumentation.  
Fluorometric titrations of drotaverine quenching of BSA fluorescence were 
carried out at various temperatures (22°C, 26°C, 32°C, 37°C and 42°C) using 10 
µM BSA and drotaverine ranging from 0-13 µM. The excitation and emission 
wavelengths were set to 280 nm and 360 nm, respectively. 
Phosphorescence measurements were made on a homemade system. 
A general description of the equipment for phosphorescence measurements has 
previously been given [9]. Since molecular oxygen is known to be a strong 
quenching agent, it was efficiently removed from the sample before the 
phosphorescence measurements. O2 removal was achieved by the application of 
moderate vacuum and inlet of ultrapure nitrogen. The pre-purified nitrogen gas 
(0.1 ppm of O2) was further purified by passing through an oxygen-trapping 
filter. This degassing procedure was additionally accompanied by the addition of 
0.3 ml of 0.1 M Na2SO3 as an O2 scavenger (final concentration of Na2SO3 in the 
sample was 0.01 M). Additionally, the presence of Na2SO3 stabilized the iodide 
solution and prevented the formation of iodine. The sample (BSA solution 
(20 μM) with 0.01 M Na2SO3) was placed in a quartz cuvette, which was 
connected to the N2/vacuum line by tubing. Five cycles of deoxygenation were 
performed. After deoxygenation, the cuvette was moved into the phosphorimeter, 
but remained attached to the tubing and was allowed to equilibrate to 30°C 
before taking measurements. The background emission was determined by 
measurements carried out before deoxygenation of the sample and was subtracted 
from the phosphorescence decay. All phosphorescence decays, after subtraction 
of the background, were analyzed in terms of a sum of exponential components 
by a nonlinear least squares fitting algorithm using the software provided by 
Origin Pro 8.0. 
The binding conformation of BSA and drotaverine was predicted using the 
Autodock 4.2 software package [10-12] which uses an empirical free energy 
force ﬁeld with a Lamarckian Genetic Algorithm to predict the binding 
conformation and the free energies of association [10]. The structures of BSA 
and drotaverine were downloaded from the RCSB protein databank [13] and the 
Drugbank database [7], respectively. Before running the docking simulation the 
BSA file was prepared using the H++ server [14] to protonate the BSA molecule 
to replicate its structure at pH 6.5. During the docking analysis the grid size was 
set to 50, 58, and 48 along X-, Y-, and Z-axis with 0.414 Å grid spacing. The 
following AutoDocking parameters were used: GA population size = 150; 
maximum number of energy evaluations = 2500000; GA crossover mode = 2 
points. The lowest binding energy conformer was searched out of ten different 
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conformers for each docking simulation. PyMOL software was also used to 
visualize the docking conformations. 
Results and Discussion 
Photophysical parameters of BSA and drotaverine 
In agreement with previous studies [15,16], the absorption spectrum of BSA 
in phosphate buffer showed the maximum at 278 nm with the molar absorption 
coefficient equal to (3.38 ± 0.08)·104 cm-1 M-1 [17]. The emission spectra of BSA 
in phosphate buffer showed the broad maximum located at about 345 nm, which 
is consistent with the previously reported literature data [18].  
Also, the fluorescence quantum yield of BSA determined using the 
comparative method of Williams et al. [19] in which tryptophan with known 
quantum yield value of 0.14 [20] was applied as a standard sample, was 
consistent with the previously reported value of 0.19 [17]. 
In the absorption spectrum of aqueous drotaverine, three maxima, located at 
242 nm, 303 nm, and 355 nm, may be noticed, in the agreement with the 
previously reported values for drotaverine hydrochloride in water [21,22]. The 
determined molar absorption coefficients were found to be (1.86 ± 0.13)·104 cm-1 
M
-1, (9.64 ±0.70) ·103 cm-1 M-1 and (1.03 ±0.07) ·104 cm-1 M-1 at 242, 303 and 
355 nm, respectively. 
The emission spectrum of aqueous drotaverine showed a structured band with 
the maximum located at 456 nm and a shoulder at 425 nm. Previously reported 
fluorescence spectrum of drotaverineHCl in 0.1 M H2SO4 showed the maximum 
located at 465 nm (after excitation at 295 nm) [23].  
Time resolved fluorescence experiments 
The decay curves of BSA fluorescence upon increasing concentration of 
drotaverine were obtained by use of excitation at 295 nm and emission at 350 
nm. The fluorescence data (fluorescence lifetimes (τ1, τ2) with their fractional 
contribution (f1, f1) to the steady state intensity), determined from a biexponential 
fit to time-resolved data, are presented in Table 1. The average lifetime of BSA 
(τav) was calculated from  [24]. The goodness of fit was judged 
from the reduced χ2 values. 
In the absence of drotaverine, the fluorescence decay of BSA was 
biexponential with the lifetimes of 6.48 ns and 2.33 ns. The shorter lifetime 
component, most probably, arises from the 134 tryptophanyl residue which is 
located in the subdomain IB of the protein and is more exposed to solvent (less 
,,buried” inside the protein) as compared to the emitting Trp213 residue located 
in the subdomain IIA, to which longer lifetime component may be assigned.  
Upon increasing concentration of drotaverine, the fluorescence decay of BSA 
was also biexponential with no considerable changes in the fluorescence lifetime 
components. Also, the calculated value of the average fluorescence lifetime of 
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BSA has not been changed significantly with increasing concentration of 
drotaverine, suggesting the involvement of static quenching mechanism.  
Table 1. Time-resolved fluorescence data of BSA upon increasing concentration 
of drotaverine 
Cdrotaverine[μM] τ1 [ns] f1 τ2 [ns] f2 τav[ns] χ
2
 
0 6.48±0.07 0.95 2.33±0.60 0.05 6.27±0.06 1.11 
7 6.38±0.05 0.96 1.51±0.35 0.04 6.20±0.04 1.20 
17 6.44±0.08 0.93 2.32±0.40 0.07 6.15±0.06 1.16 
20 6.42±0.06 0.94 2.06±0.36 0.06 6.14±0.07 1.13 
27 6.38±0.08 0.93 2.22±0.36 0.07 6.11±0.05 1.14 
Steady-state fluorescence quenching studies 
Changes in the fluorescence spectrum of BSA (with the maximum located at 
about 345 nm) upon increasing concentration of drotaverine are shown in Fig. 2. 
From Fig. 2, a considerable decrease in the fluorescence intensity of BSA may be 
seen with increasing concentration of drotaverine.  
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Figure 2. Fluorescence spectrum of BSA in phosphate buffer (33 μM) together 
with its changes upon increasing concentration of drotaverine 
Assuming that static quenching mechanism is involved in the interactions 
between BSA and drotaverine, the spectrofluorometric titration experiment was 
performed using very small doses of drotaverine within the concentration range 
of 0-13 µM at different temperatures. For each temperature, the association 
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constant (Ka) was determined using the Stern-Volmer equation (eq. 1) of the 
following form: 
       (eq. 1) 
where F0 and F are fluorescence intensities of BSA in the absence and presence 
of the quencher (drotaverine), respectively, and [Q] is the concentration of the 
quencher. An example of the Stern-Volmer plot for BSA fluorescence quenching 
by drotaverine at 22°C is presented in Fig. 3. 
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Figure 3. Stern-Volmer plot for fluorescence quenching of BSA by drotaverine 
at 22°C 
The determined Ka values together with their R
2
-values, which are the 
measure of the goodness of the fit to Stern-Volmer model, are gathered in 
Table 2. From Table 2 a decrease in Ka upon increasing temperature may be 
noticed suggesting involvement of static quenching mechanism between 
drotaverine and BSA. If the dynamic quenching mechanism prevailed, increasing 
temperature would lead to an increase in Ka because of the higher likelihood 
of collisional quenching [24].  
Table 2. The determined Stern-Volmer quenching constants (Ka) for different 
temperatures (T) 
T [K] Ka [M
-1
] R
2
 
295.15 (2.85±0.02)·104 0.999 
300.15 (2.75±0.01)·104 0.998 
305.15 (2.57±0.02)·104 0.998 
310.15 (2.31±0.04)·104 0.994 
315.15 (2.13±0.03)·104 0.994 
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Thermodynamic parameters characterizing binding of drotaverine to BSA 
Considering that binding of drotaverine to BSA is governed mainly by static 
quenching process, that is, the BSA-drotaverine complex is formed in the 
ground state, we have calculated (from Ka-values compiled in Table 2) 
the thermodynamic parameters for binding of drotaverine to BSA. The 
thermodynamic parameters such as enthalpy (∆H), free Gibbs energy (∆G) and 
entropy (∆S) were calculated by following thermodynamic equations: 
 
         (eq.2) 
     (eq. 3) 
where Ka is the binding (association) constant at the corresponding temperature 
and R is the gas constant. The obtained results are presented in Table 3.  
Table 3. Thermodynamic parameters for drotaverine binding to BSA 
T [K] ∆G [kJ/mol] ∆H [kJ/mol] ∆S [J/(Kmol)] 
295.15 -25.17 -5.57 66.40 
300.15 -25.51 -10.38 50.41 
305.15 -25.76 -16.67 29.79 
310.15 -25.91 -12.73 42.47 
It is tempting to analyze the obtained thermodynamic parameters in the light 
of the previously proposed [25] relationship between thermodynamic parameters 
and binding mode. Ross and Subramanian [25] reported the characteristic signs 
of the thermodynamic parameters associated with the various individual kinds 
of interactions that might take place in protein association processes. When 
∆H < 0 or ∆H ≈ 0 and ∆S > 0 the main acting force is electrostatic interaction 
[26]. However, it should be kept in mind, that even the electrostatic forces are 
prevailing in binding drotaverine to BSA, the contributions from hydrophobic, 
hydrogen bonding, dispersion or van der Waals forces cannot be neglected.  
Phosphorescence measurements 
To study the interactions between BSA and drotaverine in the triplet excited 
state T1, the phosphorescence lifetime of BSA was measured upon increasing 
concentrations of drotaverine at constant concentration of KI, which is a suitable 
enhancer of intersystem crossing. The obtained results (Fig. 4) showed that 
the phosphorescence lifetime (τph) of BSA increases upon increasing the 
concentration of drotaverine.  
 
Experimental and theoretical investigation of drotaverine …  
Biotechnol Food Sci, 2013, 77 (1), 25-36       http://www.bfs.p.lodz.pl 
33 
0 5 10 15 20 25 30
450
480
510
540
570
 p
h
 [

s
]
C
Drotaverine
 [M]
 
Figure 4. Phosphorescence lifetime (τph) of BSA vs increasing concentrations 
of drotaverine 
This observation confirms the existence of the intermolecular interactions 
between drotaverine and BSA in excited triplet state. Most probably, binding 
drotaverine to BSA triplet state resulted in a considerable stiffening of protein 
structure in the nearest neighborhood of the emitting tryptophan residue, which 
is manifested by the observed increase of BSA phosphorescence lifetime 
upon increasing concentration of drotaverine. This remarkable sensitivity of 
tryptophan phosphorescence lifetime to the subtle changes associated with 
binding drugs to tryptophan containing proteins indicate interesting research area 
in the pharmacokinetic and pharmacodynamics studies. 
Modeling results 
A force-field docking simulation of drotaverine to BSA was carried out in 
AutoDock 4.2 as described in the Materials and Methods section of this paper. 
The lowest energy configuration of BSA-drotaverine complex, chosen for further 
analysis, is presented in Fig. 5. The calculated binding free energy for this 
complex is ∆G = -23.77 kJ/mol at 298.15 K and correlates well with the value 
determined from fluorimetric titration experiment. Analyzing the geometrical 
parameters of the theoretically predicted BSA-drotaverine complex it may be 
noticed that the lowest energy binding site for drotaverine in BSA was in the 
vicinity of Trp213.  
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Figure 5. Graphical representation of the lowest energy conformation of 
BSA-drotaverine complex 
Conclusions 
The results of this study provided evidence for the existence of intermolecular 
interactions between drotaverine and BSA. The obtained results clearly showed 
that drotaverine quenched BSA fluorescence, and the most probable mechanism 
is static quenching. The experimentally determined free energy of drotaverine 
binding to BSA was in excellent agreement with the theoretically predicted value 
estimated from computer simulations. The AutoDock model also revealed that 
the lowest energy binding site is in drug site I in the vicinity of Trp213. Further 
research on the topic should include a more detailed study of the interactions 
in the S1 and T1 states. The investigation into the BSA-drotaverine interactions 
reported here may provide an invaluable structural framework for the 
interpretation of drug binding data and may facilitate efforts to modify new 
therapeutic compounds to control their interaction with serum albumins and 
therefore optimize drug distribution. 
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